StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE) PT Raised to $47 at BMO Capital; Sees Tafamidis as a $3.5B+ Drug
September 6, 2018 8:27 AM
BMO Capital analyst Alex Arfaei raised the price target on Pfizer (NYSE: PFE) to $47.00 (from $44.00) while maintaining an ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Pfizer (PFE) PT Raised to $48 at Cowen
September 6, 2018 10:50 AM